| Basic data
|
| (21) | Request Number: | S20180013A (Supplementary Protection Certificate granted) |
| (22) | Request Date: | 27.08.2018 |
| (43) | Request Publication Date: | 21.09.2018 |
| |
| (71) | Applicant(s): | | 1. | Pfizer Inc., 66 Hudson Boulevard East, New York, NY 10001-2192, US |
|
| (74) | Representative: | Hraste & Partneri odvjetničko društvo d.o.o.,
Ribnjak 40, 10000 Zagreb, HR
|
| |
| (68) | Basic Patent Number: | P20120104 |
| (21) | Application Number | P20120104A |
| (22) | Filing Date | 01.02.2012 |
| (54) | Title of Invention: | DIOXA-BICYCLO[3.2.1.]OCTANE-2,3,4-TRIOL DERIVATIVES |
| |
| (95) | Product Name: | ERTUGLIFLOZIN, OPCIONALNO KAO KRISTALNI OBLIK, OSOBITO KAO SUKRISTAL S L-PIROGLUTAMINSKOM KISELINOM, A SPECIFIČNO KAO ERTUGLIFLOZIN-L-PIROGLUTAMINSKA KISELINA |
| |
| (92)(93) | Number and Date of First Marketing Authorisation: | | EU/1/18/1267/001-014, 23.03.2018 |
|
| |
| (11) | SPC Number: | S20180013 |
| | Date of Grant: | 15.06.2023 |
| | Publication Date: | 23.06.2023 |
| (94) | Validity Period: | 18.08.2029 - 23.03.2033 |
| |
| | | CHANGE OF NAME AND/OR ADDRESS | | New entry: | Pfizer Inc.,
66 Hudson Boulevard East, New York, NY 10001-2192, US
| | Previous entry: | Pfizer Inc.,
235 East 42nd Street, New York, NY 10017, US
| | | Recording date: | 09.05.2023 | | | Publication date: | 26.05.2023 | |
|